Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225810 | 0.88 | POLB (0.46) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL6004537 | 0.87 | POLB (0.45) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL6002757 | 0.84 | ALDH1A1 (0.49) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL6002721 | 0.84 | GPBAR1 (0.47) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL6004396 | 0.82 | GABRA5 (0.45) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL4721410 | 0.82 | MAPT (0.42) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL6004911 | 0.82 | NPSR1 (0.43) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL4717776 | 0.81 | NPSR1 (0.43) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL4818743 | 0.81 | CNR1 (0.46) | POLBTDP1L3MBTL1GPBAR1NPSR1 | |
| SCHEMBL4832493 | 0.80 | CNR1 (0.47) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | POLB 1356/4885TDP1 583/4885L3MBTL1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.